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To the Editor: 
Sickle cell anemia (SCA) is one of the most common inherited blood disorders in the world, 
characterized by chronic hemolytic anemia and recurrent vasoocclusive pain episodes. 
Pulmonary complications are a major cause of morbidity and mortality. Individuals with SCA 
have been shown to have a high prevalence of asthma, wheezing, and airway 
hyperresponsiveness (AHR) (1, 2). Increased AHR has been demonstrated in individuals with 
SCA, both with and without a concomitant diagnosis of asthma (2, 3). Although previous 
studies have looked at the association between a history of acute chest syndrome (ACS) 
episodes and AHR to methacholine (4), investigators have not examined whether AHR to 
methacholine is a risk factor for future SCA-related morbidity (pain and ACS). Therefore, the 
aim of this study was to examine the association between AHR to methacholine and future 
rates of hospitalization for pain and ACS. 
Children with SCA (hemoglobin SS or sickle β0 thalassemia) aged 4 to 18 years were 
identified at three large clinical centers and enrolled into the Sleep and Asthma Cohort study, 
a prospective, observational cohort study designed to evaluate the contribution of 
abnormalities in sleep and asthma to SCA-related morbidity. Participants were enrolled 
without regard to previous morbidity or diagnosis of asthma. Methacholine airway challenge 
was performed as a baseline measurement when a child was well, at least 1 month after a 
hospitalization for pain or ACS. The 2-minute tidal breathing method was employed with an 
Airlife Sidestream High Efficiency nebulizer (Cardinal Health, Dublin, OH) according to 
American Thoracic Society standards, as previously described (2). Methacholine dose–
response slopes (DRS) were calculated for all participants, as previously described (2). 
Briefly, the numerator was the total percentage decrease in FEV1 during the challenge, and 
the denominator was the cumulative dose of methacholine received. A vasoocclusive pain 
episode was defined as pain associated with SCA requiring hospitalization and treatment with 
opioids. Headaches requiring hospitalization were not considered to be pain episodes. ACS 
was defined as a new density on chest roentgenogram and at least one of the following: 
increased respiratory effort (as demonstrated by a decrease in oxygen saturation or increase in 
respiratory rate) or temperature greater than 38°C. Pneumonia was included in this definition. 
ACS and pain episodes were reviewed by a single investigator at each site, with review by 
the principal investigator, who was blinded to methacholine results, to ensure a uniform 
definition of pain and ACS in this multicenter study. 
Methacholine airway challenge was performed with 99 participants. The initial 98 children 
completed testing without a serious adverse event. However, the 99th child tested developed 
his first vasoocclusive pain episode requiring hospitalization within 3 days of testing; 
methacholine challenge testing was subsequently removed from the study protocol. Of the 99 
children who completed testing, 70 participants had complete data on all covariates included 
in our multivariable models (including pain and ACS episodes from birth) and were therefore 
included in the analysis. The median duration of prospective follow-up after methacholine 
testing was 5.8 years (range, 1.4–6.6 yr). There was no significant difference in methacholine 
response between those included and those excluded from the analysis (P = 0.13). 
Multivariable negative binomial regression models were constructed to test the association 
between methacholine DRS and prospective rates of ACS and pain episodes. Covariates 
previously shown to be associated with future rates of ACS (sex, shortness of breath, and 
history of ACS before age 4 yr) and pain (age and white blood cell count) were included in 
multivariable models (5, 6). Given a nonnormal distribution, DRS was log-transformed for all 
analyses. Median rates of pain and ACS per year were 0.49 (interquartile range, 0.12–1.17) 
and 0.16 (interquartile range, 0–0.34), respectively. As shown in our final models below, 
there were no statistically significant relationships between methacholine DRS and future 
hospitalizations for ACS or pain; coupled with the 95% confidence intervals, the relationship 
between methacholine response and future rates of ACS or pain is minimal, if present at all 
(Table 1). 
Given the strong association between asthma and SCA morbidity and mortality, an important 
question has been whether lung function abnormalities, and specifically lower airway 
obstruction and/or AHR, are associated with SCA-related morbidity. A single-site study 
using spirometry obtained for clinical purposes found an association between lower airway 
obstruction and future rates of pain (7). In contrast, our group examined the association 
between lung function pattern and SCA-related morbidity among 149 children and found no 
association between obstructive pattern and future hospitalizations for pain or ACS (8). 
Chaudry and colleagues found no difference in the methacholine DRS between 50 children 
with sickle cell disease (HbSS and HbSC phenotypes) and 50 age-, sex-, and ethnically 
matched controls, and within the sickle cell disease group, there was no association between 
prior history of ACS and methacholine DRS (9). Although our results suggest that AHR, as 
measured by methacholine DRS, is not predictive of pain or ACS, it may nevertheless have 
clinical implications for pulmonary pathology in this patient population. Eiymo Mwa Mpollo 
and colleagues demonstrated that placental growth factor, an erythroid cell–derived growth 
factor that is significantly increased in individuals with SCA, augments allergen-induced 
airway inflammation and AHR in sickle mice as well as increased baseline AHR to 
methacholine through a leukotriene-dependent pathway, suggesting a novel pathway for 
potential therapeutic intervention (10). 
Limitations of this study include our small sample size, which might affect the ability to 
generalize our findings as true-negative versus false-negative results. The narrow confidence 
interval around the incidence rates of pain and ACS episodes indicate our findings are likely 
a true negative result. Our study suggests that there is neither a statistically nor clinically 
relevant relationship between methacholine responsiveness and future morbidity in children 
with SCA. 
In conclusion, although there is a high prevalence of AHR in patients with SCA (2), we 
demonstrate for the first time that AHR may not be predictive of future risk for pain or ACS. 
Further studies are needed to improve our understanding of associations between vascular 
dysfunction, pain, airway obstruction, AHR, and lung disease pathogenesis in patients with 
SCA. 
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Table 1. Multivariable Model of Prospective Rates of ACS and Pain in 70 Children with 
SCA 
Covariate IRR 95% CI P 
Value 
Multivariable model of prospective rates of ACS       
 Male sex 0.53 0.30–0.93 0.027 
 History of an ACS episode prior to 4 yr of age 2.88 1.66–4.99 <0.001 
 History of wheezing leading to shortness of breath 1.50 0.76–2.96 0.24 
 Log methacholine dose–response slope 1.11 0.98–1.27 0.108 
Multivariable model of prospective rates of vasoocclusive pain 
episodes 
      
 Age 1.12 1.04–1.20 0.004 
 White blood cell count 1.00 0.93–1.08 0.991 
 Log methacholine dose–response slope 0.97 0.85–1.11 0.654 
Definition of abbreviations: ACS = acute chest syndrome; CI = confidence interval; 
IRR = incidence rate ratio; SCA = sickle cell anemia. 
Negative binomial regression models with adjustment for overdispersion, using robust SEs. 
Two-tailed significance values are shown. 
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